The purpose of this Notice of Special Interest (NOSI) is to invite applications proposing early-phase translational research to generate new malaria vaccine candidates or monoclonal antibody (mAb)-based interventions suitable for further downstream development and clinical evaluation, particularly for Plasmodium falciparum and P. vivax.

Background

Recently, the first-generation malaria vaccine RTS,S/AS01E, and a similar vaccine, R21/Matrix M, were recommended by the World Health Organization (WHO) for broad introduction in African countries for children more than 5 months old. Additionally, emerging clinical data show that passive immunization with malaria specific mAbs could provide protection in African adults and children. To address future effective global malaria control and elimination, WHO issued revised Preferred Product Characteristics (PPC) for future malaria vaccine development calling for new strategic priorities for next generation malaria vaccines, and

Click this link to continue reading the article on the source website.